UCHL1 and oral cavity squamous cell carcinoma: LDN-57444 has been widely used to inhibit UCHL1 in several type of cancers in which UCHL1 may be expressed, such as in oral squamous cell carcinoma (OSCC) [87], neuroblastoma [88, 89], non-small cell lung cancer (NSCLC) [90] and invasive carcinomas [87].